First Manhattan
FBRX icon

First Manhattan’s Forte Biosciences FBRX Stock Holding History

First Manhattan’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5
Closed -$13K – 1351
2019
Q2 		$13K Hold
5
– – ﹤0.01% 1151
2019
Q1 		$21K Hold
5
– – ﹤0.01% 1084
2018
Q4 		$16K Hold
5
– – ﹤0.01% 1100
2018
Q3 		$31K Buy
+5
New +$19K ﹤0.01% 1059

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

First Manhattan's FBRX Position: Q3 2019 in Review

First Manhattan sold out of Forte Biosciences (FBRX) in Q3 2019, closing a stake of 5 shares — an estimated $13K sold.

First Manhattan first reported a position in FBRX in Q3 2018 and held it in 4 quarters. The position peaked at $31K in Q3 2018. 58 funds tracked by Wall St. Rank hold FBRX as of Q3 2019.

  • First Manhattan reported no remaining Forte Biosciences position as of Q3 2019 after selling out during the quarter.
  • First Manhattan sold 5 Forte Biosciences shares in Q3 2019, an estimated $13K.
  • First Manhattan first reported a position in Forte Biosciences in Q3 2018 and held it in 4 quarters.
  • First Manhattan's Forte Biosciences position peaked at $31K in Q3 2018.
  • 58 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2019.

Based on First Manhattan's 13F filing for Q3 2019, filed 13 Nov 2019.